Advances in High-Throughput Screening

AIMS & OBJECTIVES OF THE CONFERENCE

With increasing industry pressure to produce pharmaceuticals faster and faster, high-throughput technologies are critical to the drug discovery process. The challenge of identifying bioactive compounds in as shorter time as is possible is met by ever advancing screening technologies. The evidence suggests that simply expanding conventional HTS is not sufficient to meet the drug discovery needs of today. However, how does a company select the most appropriate technology for their needs? How are these technologies validated? How can HTS systems be integrated into the business? The purchase and implementation of HTS systems is highly costly. This Conference will take a look at how to get the best return possible on this investment by adopting the right strategies and selecting the right technologies for your business.

A unique opportunity to learn from leading industry experts including:

• Dr Lorenz Mayr, Technology Programme Head, Lead Discovery Center, Novartis
• Dr Giuseppe Ciaramella, Assistant Director & Head, Hit Discovery Group, Pfizer
• Dr Martin Valler, Group Leader, HTS, Boehringer-Ingelheim
• Dr Jin Li, Director, Chemical Computing, AstraZeneca
• Dr Dominique Besson, Global Head, HTS Services, Serono
• Dr Jörg Hüser, Director, HTS Technologies, Bayer Healthcare
• Dr Everard Pap, Head, Assay Technologies, HTS, Aventis
• Dr Ulf Boemer, Head, Technology Development, HTS Infrastructure, Schering
• Dr Jeffrey Weidner, Head, Screen Operations, Eli Lilly